Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
CAPLIPOINT
Dr. Sridhar Ganesan · Chennai, India
₹2,613.20
▲+0.96%Caplipoint, leveraging its R&D capabilities and global manufacturing footprint, continues to gain traction in the specialty pharmaceuticals industry, evident in its strong revenue growth.
Exchange
NSI
Currency
INR
Day range
₹2,588.10 – ₹2,642.40
52-week range
₹1,500.30 – ₹2,699.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis80% confidence
Trading in the upper third of its 1-year range suggests Caplipoint's strong execution has priced in some of its growth, warranting a cautious 'accumulate' rating until it stabilizes.
3.2% below the 1-year high · trend down
Hedge-fund memo
Today
A 0.96% gain, outpacing the market, as the stock continues to benefit from its robust growth story.
This week
Caplipoint has rallied 7.3% this week, with the stock reaching its highest level in 52 weeks.
This month
This is the stock's third consecutive month of gains, with a total return of 13.4% since April.
Bull thesis
Bear thesis
News & sentiment
Neutral
1 headlines · 1 outlets · 7d
TradingView·5d ago·neutral financial data
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| CAPLIPOINT | 198.63B | 31.07 | 19.94% | 30.90% | 19.00% |
| ERIS | 197.68B | 31.56 | 18.07% | 27.12% | 7.10% |
| JBCHEPHARM | 387.93B | 54.22 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory Hurdles
Mitigation: Monitor and adjust position based on regulatory responses and adapt to any changes in market conditions
Increased Competition
Mitigation: Continuously track emerging players and adjust the portfolio according to changing market dynamics
Business intelligence
Competitive moat
Caplipoint's proprietary technology and global manufacturing footprint serve as a significant barrier to entry, safeguarding its market position and revenue growth prospects.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Release of strong earnings driven by revenue growth and margin expansion
Thesis builder
Bull case
Strong revenue growth driven by partnerships and organic expansion will continue to propel Caplipoint's stock.
Base case
Moderate revenue growth through steady market presence and product portfolio expansion will sustain investor interest.
Bear case
Regulatory hurdles, increased competition, or economic downturns might slow revenue growth, causing a correction in the stock.
Time horizon
Medium-term (1-2 years) with sustained revenue growth and market presence driving stock appreciation.
Est. CAGR
approx 15-20% over the long term
Entry (qual.)
Accumulate at current levels when the stock is trading in the upper third of its 1-year range.
Exit (qual.)
Consider scaling down exposure when the stock corrects on signs of decelerating revenue growth or market presence erosion.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how CAPLIPOINT fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain CAPLIPOINT for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
—
Investors can consider accumulating Caplipoint shares at current levels, as the stock has shown resilience in the specialty pharmaceuticals space.
Annual income statement, oldest → newest. Live via Yahoo.
| 18.69% |
| 16.48% |
| -4.80% |
| APLLTD | 159.60B | 23.67 | 12.36% | 7.39% | 4.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,588.10
Resistance (day/52w high)
₹2,642.40
Volume
86,488
Trend
down
RSI (14)
49
MACD
bearish
MA cross
golden
50-day MA
₹2,380.82
200-day MA
₹1,951.68
vs 200-DMA
33.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%